

Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
-
$BCRX
Who’s it gonna bbbe -
$BCRX Let my people go you raskley rats
-
$BCRX BINGO
-
$BCRX Creatine levels are leveling out …good news
-
‘$BCRX I’m glad to see someone else is concerned about something not just the Sea Turd
-
$BCRX @Harrington with all the trash you spout this is about as far as your going to get buddy
-
$BCRX I think it’s time
-
$BCRX BASTARDS BASTARDS BASTARDS……….
-
$BCRX So much for that 1k share add at “this is going to be the bottom” price of 9.97.
-
$BCRX You ever felt like you’ve been stabbed in the back…just wondering?
-
-
$BCRX May help control the bleeding…sorry
-
$BCRX @experiment 626 You might have Menorrhagia you might try Neproxen it may help go try the bleeding
-
-
$BCRX Come on they temporarily halted enrollment of new individuals but continue to treat existing patients. Like @Noa said use your noggin for something other than a hat rack
-
So the trial wasn’t halted…
This is an important distinction. Enrollment was halted.
Anybody going to be surprised if they come back a week or two from now and say “yeah, it’s fine, continue enrollment”. And then Pfizer rolls in with an offer, but already has 20M shares somehow?
-
$BCRX 4.28 avg. on 20k but it hurts like hell
-
$BCRX We we’re on edge 13 hrs ago
-
$BCRX What the hell was all of that about?
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
2021-05-06 | 2021-03 | -0.26 | -0.36 | -0.1 | -38.46% |
2021-02-25 | 2020-12 | -0.25 | -0.34 | -0.09 | -36.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-04-18 | Barclays | Downgrade | Overweight | Equal-Weight |
2022-04-12 | RBC Capital | Upgrade | Sector Perform | |
2022-04-11 | B of A Securities | Downgrade | Buy | Neutral |
2022-04-11 | Oppenheimer | Upgrade | Outperform | |
2021-12-10 | Oppenheimer | Upgrade | Outperform | |
2021-11-04 | RBC Capital | Upgrade | Sector Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-04-17 | ABERCROMBIE GEORGE B | Director | 0.00 | Sale |
2022-02-27 | ASELAGE STEPHEN J | Director | 33.16K | Stock Award(Grant) |
2022-03-06 | BABU YARLAGADDA S | Officer | 230.06K | Sale |
2022-02-27 | HEGGIE THERESA | Director | 16.23K | Stock Award(Grant) |
2022-02-27 | INGRAM ROBERT ALEXANDER | Director | 80.06K | Stock Award(Grant) |
2022-02-28 | JONES MICHAEL L. | Officer | 11.20K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-03-30 | Blackrock Inc. | 14.10M | 229.30M | 7.60% |
2022-03-30 | Vanguard Group, Inc. (The) | 13.21M | 214.75M | 7.12% |
2022-03-30 | Baker Brothers Advisors, LLC | 12.71M | 206.68M | 6.85% |
2022-03-30 | FMR, LLC | 8.41M | 136.82M | 4.53% |
2022-03-30 | State Street Corporation | 7.46M | 121.34M | 4.02% |
2022-03-30 | Pictet Asset Management SA | 5.11M | 83.04M | 2.75% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-01-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 5.30M | 81.83M | 2.85% |
2021-12-30 | Vanguard Total Stock Market Index Fund | 5.11M | 70.78M | 2.75% |
2022-01-30 | iShares Russell 2000 ETF | 4.13M | 63.78M | 2.22% |
2022-02-27 | Fidelity Select Portfolios - Biotechnology | 2.85M | 47.28M | 1.53% |
2021-12-30 | Vanguard Extended Market Index Fund | 2.41M | 33.40M | 1.30% |
2021-12-30 | Artisan International Small-Mid Fund | 1.89M | 26.13M | 1.02% |
Dividend | Date |
---|---|
0 | 2014-06-11 |
0 | 2014-06-05 |
0 | 2014-05-20 |
0 | 2014-05-16 |
0 | 2014-04-02 |